This study evaluated the costs and cost-effectiveness of a shcool-based grade 6 universal vaccination program against hepatitis B. Methods.
We performed a descriptive cost study and cost-effectiveness analysis of British Columbia's vaccination program for 1994 and 1995.
Since 1992, public health nurses have administered hepatitis B vaccine to grade 6 students in shcools.
We measured costs of vaccine, vaccine administration, and net program costs and used a validated Markov model to calculate the cost-effectiveness of the program.
Vaccinating each student cost $44, $24 of which was the cost of vaccine administration.
The net cost was $9 per person ; considering productivity costs, net savings were $75 per person.
Marginal cost per life year gained was $2100.
Universal adolescent vaccination is also economically attractive in regions with incidence rates below 3 cases per 100 00 per year.
Hepatitis B vaccine can be delivered in North American schools at a reasonable cost.
Adolscent veccination is economically attractive in North American regions of high and average incidence rates.
Our analysis supports vaccination in adolescents who remain at risk for hepatitis B virus infection.
Mots-clés Pascal : Hépatite virale B, Virose, Infection, Immunoprophylaxie, Prévention, Vaccination, Programme sanitaire, Analyse coût efficacité, Economie santé, Enfant, Homme, Age scolaire, Appareil digestif pathologie, Foie pathologie
Mots-clés Pascal anglais : Viral hepatitis B, Viral disease, Infection, Immunoprophylaxis, Prevention, Vaccination, Sanitary program, Cost efficiency analysis, Health economy, Child, Human, School age, Digestive diseases, Hepatic disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0004411
Code Inist : 002B05C02G. Création : 31/05/1999.